Mast launches new Anyplex II human papillomavirus assays

Mast has announced the launch of two new assays for the detection of human papillomavirus, which were originally developed by Seegene.

The Anyplex II HPV 28 assay differentiates and quantifies 19 high-risk and nine low-risk genotype of the virus, offering comprehensive automated genotyping capabilities with only two tubes and no post-PCR processing requirement.

Meanwhile, the Anyplex II HPV HR assay offers fast and reliable detection, differentiation and quantification of 14 high-risk viral genotypes in a single tube, delivering better results than existing screening platforms without loss of throughput or additional labour required.

Seegene's proprietary technologies, including DPO, TOCE and MuDT, are known for their ability to simultaneously detect up to 28 targets per sample with no post-PCR processing, with high sensitivity, specificity and reproducibility.

The company said: "Anyplex II overcomes the limitations of other products in the market by offering a more comprehensive subtyping capability."

Human papillomavirus is the leading cause of cervical cancer in women, with more than 150 different types having been identified, although only a subset are implicated as major risk factors for cervical cancer.

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.